The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration

Published:2018-02-05 Issue:4 Volume:61 Page:1622-1635
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Adams Christopher M.¹^ORCID,Anderson Karen²,Artman Gerald¹,Bizec Jean-Claude³,Cepeda Rosemarie²,Elliott Jason¹,Fassbender Elizabeth²,Ghosh Malay⁴,Hanks Shawn²,Hardegger Leo A.¹,Hosagrahara Vinayak P.³,Jaffee Bruce²,Jendza Keith¹,Ji Nan¹,Johnson Leland¹,Lee Wendy³,Liu Donglei¹,Liu Fang²,Long Debby²,Ma Fupeng¹,Mainolfi Nello¹,Meredith Erik L.¹,Miranda Karl¹,Peng Yao⁵,Poor Stephen²,Powers James¹,Qiu Yubin²,Rao Chang¹,Shen Siyuan²,Sivak Jeremy M.²,Solovay Catherine¹,Tarsa Peter⁶,Woolfenden Amber²,Zhang Chun¹,Zhang Yiqin²

Affiliation:

1. Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States

2. Ophthalmology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States

3. Pharmacokinetic Sciences, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge Massachusetts 02139, United States

4. Global Drug Development/Technical Research & Development, Novartis Pharmaceutical Corporation, 6201 South Freeway Fort Worth, Texas 76134-2099, United States

5. Ocular Pharmacokinetics and Disposition, Alcon, a Novartis Company, 201 South Freeway, Fort Worth, Texas 76134, United States

6. Chemical and Pharmaceutical Profiling, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States

Funder

Novartis

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b01731

Reference39 articles.

2. Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition

3. DIFFERENTIAL EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR-A ISOFORMS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

4. The Biology of Vascular Endothelial Growth Factor

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I Study of Tivozanib Eye Drops in Healthy Volunteers and Patients with Neovascular Age-Related Macular Degeneration;Ophthalmology Science;2024-11

2. Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications;Frontiers in Medicine;2024-07-19

3. Age-Related Macular Degeneration - Therapies and Their Delivery;Current Drug Delivery;2024-06

4. New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies;Biochimica et Biophysica Acta (BBA) - General Subjects;2024-06

5. Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration;Archives of Pharmacal Research;2024-06